Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials.
Irvine, United States. In Alzheimers Res Ther, Dec 2014
RESULTS: North America, Western Europe/Israel, and Australia/South Africa enrolled similar proportions of men, apolipoprotein E ε4 carriers, and participants with spouse study partners, whereas Asia, Eastern Europe/Russia, and South America/Mexico had lower proportions for these variables.
Cholesterol and metal ions in Alzheimer's disease.
Ann Arbor, United States. In Chem Soc Rev, Nov 2014
For example, (a) cholesterol has been shown to be misregulated in AD-afflicted brains, and the aberrant activity of proteins (particularly, apolipoprotein E (ApoE) and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (HMGR)) has been linked to cholesterol-related AD exacerbation; (b) dyshomeostasis of metal ions associated with misfolded proteins (i.e., amyloid-β (Aβ) aggregates) found in the brains of AD patients is shown to promote oxidative stress leading to the malfunction of multiple proteins, including cytochrome c oxidase (CcO), and Cu/Zn superoxide dismutase (SOD1); (c) metal ion misregulation has also been observed to disrupt the activity of proteins (e.g., HMGR, low-density lipoproteins (LDL)), required for cholesterol production and regulation.
Rockville, United States. In Unknown Journal, 0001
OBJECTIVE: We assessed four pharmacogenetic tests: 1) cytochrome P450, subfamily IIC, polypeptide 9 (CYP2C9), 2) vitamin K epoxide reductase subunit protein 1 (VKORC1), 3) apolipoprotein E (Apo E), and 4) methylenetetrahydrofolate reductase (MTHFR) for their associations with patient’s response to therapy with warfarin (CYP2C9 and VKORC1), statins (Apo E), or antifolate chemotherapy (MTHFR).